D.E. Shaw & Co
CRMD icon

D.E. Shaw & Co’s CorMedix CRMD Stock Holding History

D.E. Shaw & Co’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
+171,807
New +$1.36M ﹤0.01% 3538
2026
Q1 		– Sell
-106,374
Closed -$1.24M – 4622
2025
Q4 		$1.24M Buy
+106,374
New +$1.18M ﹤0.01% 3395
2025
Q3 		– Sell
-219,804
Closed -$2.71M – 4612
2025
Q2 		$2.71M Sell
219,804
-10,798
-5% -$119K ﹤0.01% 2514
2025
Q1 		$1.42M Sell
230,602
-215,812
-48% -$2.23M ﹤0.01% 2848
2024
Q4 		$3.62M Buy
446,414
+125,425
+39% +$1.25M ﹤0.01% 2246
2024
Q3 		$2.59M Buy
320,989
+190,745
+146% +$1.03M ﹤0.01% 2496
2024
Q2 		$564K Buy
130,244
+873
+0.7% +$4.43K ﹤0.01% 3551
2024
Q1 		$549K Sell
129,371
-13,906
-10% -$48.2K ﹤0.01% 3435
2023
Q4 		$539K Sell
143,277
-42,972
-23% -$148K ﹤0.01% 3479
2023
Q3 		$689K Buy
186,249
+134,945
+263% +$537K ﹤0.01% 3291
2023
Q2 		$203K Sell
51,304
-75,005
-59% -$371K ﹤0.01% 3733
2023
Q1 		$523K Sell
126,309
-18,527
-13% -$75.8K ﹤0.01% 3535
2022
Q4 		$611K Buy
144,836
+93,487
+182% +$331K ﹤0.01% 3744
2022
Q3 		$145K Buy
51,349
+37,529
+272% +$156K ﹤0.01% 4547
2022
Q2 		$56K Buy
13,820
+2,325
+20% +$8.64K ﹤0.01% 4826
2022
Q1 		$63K Buy
+11,495
New +$52.6K ﹤0.01% 5087
2021
Q1 		– Sell
-42,821
Closed -$318K – 4110
2020
Q4 		$318K Buy
+42,821
New +$291K ﹤0.01% 3581
2020
Q1 		– Sell
-30,306
Closed -$221K – 3971
2019
Q4 		$221K Buy
+30,306
New +$185K ﹤0.01% 3764

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

D.E. Shaw & Co's CRMD Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in CorMedix (CRMD) in Q2 2026: 171,807 shares worth $1.35M. The stake represents ﹤0.01% of the portfolio and ranks #3538 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in CRMD as recently as Q4 2025.

D.E. Shaw & Co first reported a position in CRMD in Q4 2019 and has held it in 18 quarters since. The position peaked at $3.62M in Q4 2024. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • D.E. Shaw & Co held 171,807 shares of CorMedix worth $1.35M as of Q2 2026.
  • CorMedix was a new D.E. Shaw & Co position in Q2 2026.
  • CorMedix made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3538 holding.
  • D.E. Shaw & Co first reported a position in CorMedix in Q4 2019 and has held it in 18 quarters since.
  • D.E. Shaw & Co's CorMedix position peaked at $3.62M in Q4 2024.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.